Understanding Alzheimer’s and Dementia: Early Signs and Importance of Awareness

The Significance of Early Detection

Recognizing the early signs and symptoms of Alzheimer’s disease and dementia is crucial for those caring for older individuals. For instance, misplacing keys in the refrigerator may indicate mere absent-mindedness or fatigue, but it can also signal a need for health preservation measures. In Canada, approximately half a million people are currently living with Alzheimer’s disease, and projections show that this number could double within the next decade. As the prevalence of this condition increases, awareness becomes essential for early detection, fostering compassion, advancing research, and enhancing care and support services for those affected.

Alzheimer’s Awareness Month

Every January, the Alzheimer Society leads Alzheimer’s Awareness Month, collaborating with global organizations to raise awareness about Alzheimer’s disease and dementia. This non-profit organization is dedicated to providing support, education, and advocacy for individuals living with dementia, as well as their families and caregivers. Navigating a dementia diagnosis can be challenging, making it important to connect with your local Alzheimer Society. They serve as a vital resource, known as First Link®, offering programs and services that create a supportive community for affected individuals and their loved ones.

Symptoms of Alzheimer’s Disease

Common Warning Signs

The primary symptoms indicating the onset of dementia include:
– Memory loss and forgetfulness
– Difficulty concentrating
– Loss of practical skills (e.g., dressing, cooking)
– Disorientation regarding time and place
– Impaired cognitive functions
– Challenges in interpreting information
– Speech difficulties
– Apathy and loss of interest in activities
– Issues with self-care and communication

Treatment Options for Alzheimer’s

Current Medications

While there is no cure for Alzheimer’s disease, Health Canada has approved several medications that can slow disease progression and manage symptoms. The two main categories of treatment include:
– Cholinesterase inhibitors (e.g., Donepezil, Galantamine), which help prevent the breakdown of acetylcholine, a chemical essential for learning and memory.
– NMDA receptor antagonists (e.g., Memantine), which lower glutamate levels that, when excessive, can harm brain cells.

Reducing the Risk of Alzheimer’s Disease

Preventive Measures

Research indicates that maintaining an active lifestyle can mitigate the risk of developing dementia. Engaging in regular exercise, resistance training, social activities, and brain exercises can be beneficial. Brain training means challenging the mind through various activities rather than repetitive tasks. Listening to music, solving puzzles, and participating in hobbies are effective ways to keep the brain healthy. Maintaining social connections is also crucial for mental engagement.

2023 Updates on Alzheimer’s Research and Treatments

New Drug Developments

In 2023, two groundbreaking drugs from a new class of treatments garnered attention for their ability to eliminate amyloid plaques linked to Alzheimer’s disease. In January, the FDA approved lekanemab (Lekembi) for early-stage Alzheimer’s patients. While it reportedly slows cognitive decline by 27%, its clinical significance remains debated, especially considering its annual cost of $26,500 and potential side effects. Moreover, recent phase III clinical trial results for donanemab showed promising outcomes, with half of the participants not experiencing disease progression.

Recent Research Findings

Alzheimer’s Disease International releases the World Alzheimer Report annually, highlighting significant findings. The 2023 report emphasized the following:
– Sleep disturbances may increase the risk of dementia.
– Football players, excluding goalkeepers, are at a heightened risk of dementia due to frequent heading of the ball.
– Long-term hormone replacement therapy could elevate the risk of developing dementia.
– New gene mutations that provide protection against Alzheimer’s disease have been identified.

Explore our 2023 Alzheimer’s and dementia stories for more insights, including topics on memory, prevention strategies, and the impact of animal therapy.

References

1. Alzheimer’s Awareness Month. Alzheimer Society of Canada. Accessed November 25, 2023. https://alzheimer.ca/en/take-action/change-minds/alzheimers-awareness-month
2. Alzheimer Society. The 10 warning signs of dementia. Alzheimer Society of Canada. Accessed November 25, 2023. https://alzheimer.ca/en/about-dementia/do-i-have-dementia/10-warning-signs-dementia
3. Medications approved to treat Alzheimer’s disease in Canada. Alzheimer Society of Canada. Accessed November 25, 2023. https://alzheimer.ca/en/about-dementia/how-can-i-treat-dementia/medications-approved-treat-alzheimers-disease-canada
4. What should Canadians know about lecanemab’s U.S. FDA approval? Alzheimer Society of Canada. Published January 11, 2023. Accessed November 28, 2023. https://alzheimer.ca/en/whats-happening/news/lecanemab-leqembi-canada-fda
5. What should Canadians know about donanemab’s initial drug trial release? Alzheimer Society of Canada. Published May 30, 2023. Accessed November 28, 2023. https://alzheimer.ca/en/whats-happening/news/what-should-canadians-know-about-donanemabs-initial-drug-trial-release
6. Long S., et al. World Alzheimer Report 2023. Alzheimer’s Disease International. Published September 2023. Accessed November 28, 2023. https://www.alzint.org/u/World-Alzheimer-Report-2023.pdf
7. What the FDA Approval of Lecanemab Means for Patients and Families: A Q&A with MBWC Clinicians. University of Washington Medicine Memory and Brain Wellness Center. Published July 7, 2023. Accessed December 15, 2023. https://depts.washington.edu/mbwc/news/article/lecanemab